Milata Mary Abraham is a prominent inventor based in Indianapolis, IN (US), known for her significant contributions to the fields of diabetes and obesity treatment. With a total of three patents to her name, she has made remarkable strides in medical innovation.

Latest Patents

Her latest patents include "Incretin analogs and uses thereof," which provide analogs that exhibit activity at glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) receptors. These incretin analogs are designed with structural features that ensure balanced activity and an extended duration of action at these receptors. The methods outlined in this patent aim to treat various diseases, including type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and obesity. Another notable patent is "Long acting amylin receptor agonists and uses thereof," which focuses on compounds that agonize the amylin receptor, potentially lowering food intake, body weight, glucose, and triglycerides. This patent also includes pharmaceutical compositions and therapeutic uses for treating diabetes, obesity, and dyslipidemia.

Career Highlights

Milata Mary Abraham is currently employed at Eli Lilly and Company, where she continues to advance her research and development efforts in the medical field. Her work has been instrumental in creating innovative solutions for chronic health issues.

Collaborations

Some of her notable coworkers include Hongchang Qu and Jorge Alsina-Fernandez, with whom she collaborates to further enhance the impact of her inventions.

Conclusion

Milata Mary Abraham's contributions to the medical field, particularly in diabetes and obesity treatment, highlight her role as a leading inventor. Her innovative patents and ongoing work at Eli Lilly and Company demonstrate her commitment to improving health outcomes for patients.

This text is generated by artificial intelligence and may not be accurate.